Lataa...
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed RTS,S/AS01 vaccine efficacy against malaria. We now present in-depth safety results from this study. 8922 children (enrolled at 5–17 months) and 6537 infants (enrolled at 6–12 weeks) were 1:1:1-randomi...
Tallennettuna:
| Julkaisussa: | Hum Vaccin Immunother |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6816384/ https://ncbi.nlm.nih.gov/pubmed/31012786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1586040 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|